This study is among the first in the development of SCF Pharma's omega-3 moisturizing products. Its aim is to evaluate the potential of a combined treatment of serum and cream in eczema care. Sixteen participants with eczema will be recruited at the Rimouski site. The study also seeks to verify whether these products can cause irritation. This study extends over a total period of seven weeks. 

Fatty acids are the basic building blocks of fats found in all living organisms. The essential fatty acids are divided into two main subcategories: omega-3 and omega-6. These oils are naturally present almost everywhere in consumer products. They oppose each other in their mechanism of action at the molecular level. It is widely recognized in the scientific literature that omega-3s have anti-inflammatory properties as opposed to omega-6s which have mechanisms of action that promote inflammation. In food, it is relatively easy to make choices in favor of omega 3. In skin care, however, it is much more difficult to find products with an omega-3 fatty compound. Considering that skin can be sensitive to many irritating factors, it's natural to wish that the base ingredients of a moisturizer has naturally anti-inflammatory properties rather than the other way around. SCF Pharma, which specializes in pre-activated omega-3 oils (monoglycerides or MAG), is currently developing a line of moisturizing products to address this need.

Omega-3 monoglycerides (MAG-O3) developed by SCF Pharma are a new generation of omega-3s that are believed to be more effective due to their better absorption by the body. Omega-3s are generally ingested as dietary supplements in the form of ethyl esters which require several steps of metabolization before they can be absorbed by the tissues. Monoglycerides (MAG) are the final form of these metabolization steps. MAG-03 acts at the cellular level to activate the production of SPM (specialized pro-resolution mediators) which are key players against inflammation. The potential applications of MAG-03 in resolving inflammation are multiple, both in the form of supplements and at the topical level. The skin is an organ that undergoes various attacks producing inflammation. Eczema is a common manifestation of skin inflammation. To treat skin inflammation, a cream base consisting of water and a fatty substance is generally combined with an active medication. Thus, MAG-03 could play the roles of fatty substance and active ingredient simultaneously.

This study aims to evaluate the potential of a combined topical treatment of omega-3 serum and cream in the care of eczema. Applicants must be at least 18 years old, have been diagnosed with eczema by a doctor, and have not used corticosteroids in the 14 days before the start of the study. Participants will be asked to apply the treatment daily for a period of six consecutive weeks. During the first visit, the study will be explained to the candidate. If the candidate meets the eligibility criteria and is still interested in participating, the candidate may be enrolled in the study.